Saurashtra News

Osteosarcoma Market Size, Treatment, Epidemiology, Therapies and Companies by DelveInsight | Eleison Pharmaceuticals, Aadi Bioscience, GlaxoSmithKline, Bayer, Eisai Limited and Others

 Breaking News
  • No posts were found

Osteosarcoma Market Size, Treatment, Epidemiology, Therapies and Companies by DelveInsight | Eleison Pharmaceuticals, Aadi Bioscience, GlaxoSmithKline, Bayer, Eisai Limited and Others

November 18
13:41 2021
Osteosarcoma Market Size, Treatment, Epidemiology, Therapies and Companies by DelveInsight | Eleison Pharmaceuticals, Aadi Bioscience, GlaxoSmithKline, Bayer, Eisai Limited and Others
Osteosarcoma Market

DelveInsight’s “Osteosarcoma Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Osteosarcoma (OS), historical and forecasted epidemiology as well as the  Osteosarcoma (OS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the key facts of the Osteosarcoma Market Report:

  • Osteosarcoma therapeutic market in the 7MM was USD 72.50 million in 2017.
  • Osteosarcoma (OS) is a relatively rare tumour of bone with a worldwide Prevalence of 3.4 cases per million people per year. 
  • As per DelveInsight estimates, the Incident cases of Osteosarcoma in the 7MM were 2,228 cases in 2020 during the study period (2018–2030).
  • The incident cases of Osteosarcoma in the United States was 1,174 patients in 2020.
  • Our Reports estimate that males have higher cases in comparison to females. In 2020, males and females accounted for 620 and 554 cases of Osteosarcoma.
  • Based on the stages of cancer, Osteosarcoma is categorized into localized, regional, and distant stages. Localized and regional are further defined as non-metastatic, whereas, the ‘distant’ stage is defined as metastasis. The localized and regional stage incident cases accounted for 387 and 563 cases in 2020. In the same year, distant staged Osteosarcoma cases contributed to 223 cases in the US.
  • Various companies are developing therapies for the treatment of patients with Osteosarcoma i.e. Lenvatinib (Eisai Limited), Regorafenib (Bayer), Cabozantinib S-malate (Exelixis), Pazopanib Hydrochloride and Topotecan Hydrochloride (GSK), Bempegaldesleukin (NKTR-214) Plus Nivolumab (Nektar therapeutics).

 

Request for sample pages: https://www.delveinsight.com/sample-request/osteosarcoma-market

 

Key benefits of the Osteosarcoma report:

  • Osteosarcoma (OS) market report covers a descriptive overview and comprehensive insight of the Osteosarcoma (OS) epidemiology and Osteosarcoma (OS) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  • The Osteosarcoma (OS) market report provides insights on the current and emerging therapies.
  • Osteosarcoma (OS) market report provides a global historical and forecasted market covering drug outreach in 7MM.
  • The Osteosarcoma (OS) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Osteosarcoma (OS) market.

 

The key players involved in the Osteosarcoma market:

  • Eleison Pharmaceuticals 
  • Aadi Bioscience
  • GlaxoSmithKline
  • Bayer
  • Eisai Limited
  • Exelixis
  • Nektar Therapeutics
  • Cellectar Biosciences
  • And Many Others

 

Request for sample pages: https://www.delveinsight.com/sample-request/osteosarcoma-market

 

Osteosarcoma Overview

Osteosarcoma (also called osteogenic sarcoma) is the most common type of cancer that starts in the bones. The cancer cells in these tumors look like early forms of bone cells that normally help make new bone tissue, but the bone tissue in an osteosarcoma is not as strong as that of normal bones. 

 

The launch of the emerging therapies is expected to significantly impact the Osteosarcoma treatment scenario in the upcoming years:-

 

Some of Osteosarcoma Drug covered

  1. Inhaled lipid-complexed cisplatin
  2. ABI-009
  3. Lenvatinib
  4. Regorafenib
  5. Cabozantinib S-malate
  6. Pazopanib Hydrochloride and Topotecan Hydrochloride
  7. Bempegaldesleukin (NKTR-214) Plus Nivolumab
  8. CLR 131
  9. And Many Others

 

Request for sample pages: https://www.delveinsight.com/sample-request/osteosarcoma-market

 

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Osteosarcoma (OS) Patient Share (%) Overview at a Glance

5. Osteosarcoma (OS) Market Overview at a Glance

6. Osteosarcoma (OS) Disease Background and Overview

7. Osteosarcoma (OS) Epidemiology and Patient Population

8. Country-Specific Patient Population of Osteosarcoma (OS)

9. Osteosarcoma (OS) Current Treatment and Medical Practices

10. Unmet Needs

11. Osteosarcoma (OS) Emerging Therapies

12. Osteosarcoma (OS) Market Outlook

13. Country-Wise Osteosarcoma (OS) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Osteosarcoma (OS) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Request for Detailed TOC: https://www.delveinsight.com/sample-request/osteosarcoma-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/osteosarcoma-market

Related Articles